[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:acute-lymphoblastic-leukemia:t-9-22-q34-1-q11-2":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Acute Lymphoblastic Leukemia","t(9;22)(q34.1;q11.2)",4,[8,16,24,30],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT03263572","Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed\u002FRefractory, Acute Lymphoblastic Leukemia",[12],"Phase 2","RECRUITING","2026-08-26T02:16:08.402952Z","2026-05-05T02:43:28.640935Z",{"nct_id":17,"title":18,"phases":19,"status":21,"updated_at":22,"content_modified":23},"NCT07614022","A Phase I Study of LP-118 In Combination With Ponatinib, Dexamethasone And Blinatumomab For Adults With Newly-Diagnosed, BCR::ABL1-Positive ALL",[20],"Phase 1","NOT_YET_RECRUITING","2026-08-26T02:16:39.977107Z","2026-05-29T15:36:40.232902Z",{"nct_id":25,"title":26,"phases":27,"status":21,"updated_at":28,"content_modified":29},"NCT07178912","Phase II Study of the Combination of Subcutaneous Blinatumomab and Olverembatinib in Patients With Philadelphia Chromosome (ph)-Positive and\u002For BCR::ABL1 Positive Acute Lymphoblastic Leukemia (ALL)",[12],"2026-08-26T02:18:15.214990Z","2026-05-05T02:43:28.335420Z",{"nct_id":31,"title":32,"phases":33,"status":34,"updated_at":35,"content_modified":36},"NCT06773936","Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia",[12],"ENROLLING_BY_INVITATION","2026-08-26T02:15:24.145250Z","2026-06-16T05:54:07.771453Z"]